Tag: XNW27011

AACR 2026: Emerging Antibody-Drug Conjugates for the Treatment of Solid Tumors (Part 1)

Astellas Pharma and Evopoint Biosciences announced the have entered into an exclusive license agreement for XNW27011, a novel investigational clinical-stage antibody-drug conjugate (ADC) targeting CLDN18.2 (see ADC Drugmap). The agreement grants Astellas a worldwide exclusive license to develop and commercialize XNW27011.